Compare Citius Pharmaceuticals Inc (CTXR) vs Ryanair Holdings plc (RYAAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Ryanair Holdings plc — how do they compare? Citius Pharmaceuticals Inc trades at $0.49 (market cap $13.62M), while Ryanair Holdings plc trades at $53.75 (market cap $27.11B). The key difference: Ryanair Holdings plc is far larger — about 1990.5× Citius Pharmaceuticals Inc's market cap, and Ryanair Holdings plc pays a 1.66% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 16 Days and Ryanair Holdings plc for 72 Days on average.
| CTXR | RYAAY | |
|---|---|---|
Market Cap | $13.62M | $27.11B |
Volume | 132,438 | 2,427,380 |
Sector | Health | Industrials |
52-Week High | $1.82 | $73.82 |
52-Week Low | $0.48 | $51.95 |
Typical Hold Time | 16 Days | 72 Days |
Enterprise Value | $3.79M | $24.18B |
Dividend Yield | — | 1.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
RYAAY trades at $56.00, up 0.24% on the day, with a bearish technical signal despite strong fundamentals. The company reported $13.95B revenue and $1.61B net income for 2025, with valuation ratios appearing attractive (P/E 13.43, EV/EBITDA 6.05). Recent news highlights CEO commentary on Boeing MAX 10 delays and fuel cost concerns, while analyst consensus remains positive with 65% buy ratings.
RYAAY presents a value opportunity with solid profitability metrics (ROE 22.41%, net margin 12.13%) but faces near-term headwinds from oil price volatility and operational challenges. The stock's current bearish technical positioning contrasts with fundamental strength, creating potential for recovery if fuel costs stabilize and traffic targets are met.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Ryanair Holdings plc
Ryanair is the leading airline group by passenger numbers in Europe. The company employs a low-cost no-frills model to offer low fares to leisure customers on short-haul intra-European routes. In 2020, the most recent pre-pandemic fiscal year, the company carried 149 million passengers, utilizing a fleet of 467 Boeing 737 aircraft across its 1,800 routes. To keep costs low the company serves predominantly lower-cost secondary airports. The company generated sales of EUR 8.5 billion in fiscal 2020.
Read more on RYAAY →
